9.19
price up icon3.49%   0.31
pre-market  Pre-market:  9.19  
loading
Aurinia Pharmaceuticals Inc stock is traded at $9.19, with a volume of 960.81K. It is up +3.49% in the last 24 hours and up +17.37% over the past month. Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing AUR200, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.
See More
Previous Close:
$8.88
Open:
$9.14
24h Volume:
960.81K
Relative Volume:
0.67
Market Cap:
$1.24B
Revenue:
$175.51M
Net Income/Loss:
$-78.02M
P/E Ratio:
-17.34
EPS:
-0.53
Net Cash Flow:
$-34.18M
1W Performance:
+3.84%
1M Performance:
+17.37%
6M Performance:
+14.45%
1Y Performance:
+68.62%
1-Day Range:
Value
$9.075
$9.26
1-Week Range:
Value
$8.55
$9.26
52-Week Range:
Value
$5.195
$10.67

Aurinia Pharmaceuticals Inc Stock (AUPH) Company Profile

Name
Name
Aurinia Pharmaceuticals Inc
Name
Phone
250-744-2487
Name
Address
#140, 14315 - 118 AVENUE, EDMONTON, BC
Name
Employee
300
Name
Twitter
@AuriniaPharma
Name
Next Earnings Date
2024-11-07
Name
Latest SEC Filings
Name
AUPH's Discussions on Twitter

Compare AUPH with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
AUPH
Aurinia Pharmaceuticals Inc
9.19 1.20B 175.51M -78.02M -34.18M -0.53
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
476.95 120.73B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
572.39 60.56B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
325.64 42.41B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
575.42 34.96B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
294.83 31.99B 3.81B -644.79M -669.77M -6.24

Aurinia Pharmaceuticals Inc Stock (AUPH) Upgrades & Downgrades

Date Action Analyst Rating Change
Nov-04-22 Downgrade Oppenheimer Outperform → Perform
May-05-22 Resumed Cantor Fitzgerald Overweight
Dec-10-21 Upgrade Oppenheimer Perform → Outperform
Oct-28-21 Downgrade Oppenheimer Outperform → Perform
Jan-25-21 Reiterated H.C. Wainwright Buy
Nov-03-20 Reiterated H.C. Wainwright Buy
Jun-17-20 Initiated BTIG Research Buy
May-05-20 Initiated Cowen Outperform
Jan-10-20 Initiated Jefferies Buy
Dec-16-19 Reiterated H.C. Wainwright Buy
Mar-16-18 Reiterated Cantor Fitzgerald Overweight
Feb-08-18 Initiated RBC Capital Mkts Outperform
Oct-30-17 Reiterated H.C. Wainwright Buy
May-18-17 Reiterated H.C. Wainwright Buy
Apr-11-17 Initiated Cantor Fitzgerald Overweight
Mar-22-17 Reiterated FBR & Co. Outperform
Dec-30-16 Reiterated H.C. Wainwright Buy
Aug-17-16 Reiterated H.C. Wainwright Buy
Jun-30-16 Initiated H.C. Wainwright Buy
May-08-15 Initiated MLV & Co Buy
View All

Aurinia Pharmaceuticals Inc Stock (AUPH) Latest News

pulisher
Jul 23, 2025

What analysts say about Aurinia Pharmaceuticals Inc. stockDynamic profit expansion - Autocar Professional

Jul 23, 2025
pulisher
Jul 23, 2025

Is Aurinia Pharmaceuticals Inc. a good long term investmentUnmatched profit potential - Autocar Professional

Jul 23, 2025
pulisher
Jul 22, 2025

What drives Aurinia Pharmaceuticals Inc. stock priceHigh-yield investments - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 22, 2025

Aurinia Pharmaceuticals to Release Second Quarter 2025 Financial and Operational Results on July 31, 2025 - BioSpace

Jul 22, 2025
pulisher
Jul 22, 2025

Aurinia Pharmaceuticals to Announce Q2 2025 Financial Results - TipRanks

Jul 22, 2025
pulisher
Jul 22, 2025

Aurinia Pharmaceuticals: LUPKYNIS Growth and AUR200 Pipeline Fuel Long-Term Value - AInvest

Jul 22, 2025
pulisher
Jul 22, 2025

ISS Recommends That Aurinia Shareholders Vote "FOR" All Proposals at 2025 Annual General Meeting - Yahoo.co

Jul 22, 2025
pulisher
Jul 22, 2025

Aurinia Pharmaceuticals Inc. Stock Analysis and ForecastBreakthrough investment results - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 20, 2025

(AUPH) Technical Data - news.stocktradersdaily.com

Jul 20, 2025
pulisher
Jul 18, 2025

Aurinia Pharmaceuticals (NASDAQ:AUPH) Delivers Shareholders Favorable 52% Return Over 1 Year, Surging 5.5% in the Last Week Alone - 富途牛牛

Jul 18, 2025
pulisher
Jul 17, 2025

Zacks Industry Outlook Highlights Aurinia Pharmaceuticals, Heron Therapeutics, Esperion Therapeutics, Pyxis Oncology and Plus Therapeutics - Yahoo

Jul 17, 2025
pulisher
Jul 15, 2025

What makes Aurinia Pharmaceuticals Inc. stock price move sharplyDaily Breakout Picks - Newser

Jul 15, 2025
pulisher
Jul 15, 2025

How Aurinia Pharmaceuticals Inc. stock performs during market volatilityFree Stock Investment Discussion Area - Newser

Jul 15, 2025
pulisher
Jul 15, 2025

Why Aurinia Pharmaceuticals Inc. stock attracts strong analyst attentionReal Trader Insights - Newser

Jul 15, 2025
pulisher
Jul 10, 2025

How did AUPH's Q3 2024 earnings surprise impact short-term traders? - AInvest

Jul 10, 2025
pulisher
Jul 09, 2025

Trading (AUPH) With Integrated Risk Controls - news.stocktradersdaily.com

Jul 09, 2025
pulisher
Jul 08, 2025

Wheat from chaff in BAFF: APRIL’s advent for Aurinia? - BioWorld MedTech

Jul 08, 2025
pulisher
Jul 07, 2025

The Play On Aurinia Pharmaceuticals: Rising Cash Flow Provides Opportunity (NASDAQ:AUPH) - Seeking Alpha

Jul 07, 2025
pulisher
Jul 06, 2025

Retail Bulls Charge Into Aurinia Pharmaceuticals Ahead Of Autoimmune Trial Results - MSN

Jul 06, 2025
pulisher
Jul 02, 2025

Implied Volatility Surging for Aurinia Pharmaceuticals Stock Options - Nasdaq

Jul 02, 2025
pulisher
Jul 02, 2025

Implied Volatility Surging For Aurinia Pharmaceuticals Stock Options - Barchart.com

Jul 02, 2025
pulisher
Jul 01, 2025

Leerink Partners Keeps Their Buy Rating on Aurinia Pharmaceuticals (AUPH) - The Globe and Mail

Jul 01, 2025
pulisher
Jun 30, 2025

Aurinia’s aritinercept shows promising results in phase 1 study - Investing.com

Jun 30, 2025
pulisher
Jun 30, 2025

Aurinia Announces Positive Results from Phase 1 Study of Aritinercept (AUR200) - New Castle News

Jun 30, 2025
pulisher
Jun 29, 2025

(AUPH) Trading Report - news.stocktradersdaily.com

Jun 29, 2025
pulisher
Jun 29, 2025

Aurinia Pharmaceuticals to Host Conference Call to Discuss AUR200 Phase 1 Study Results on June 30, 2025 - The Joplin Globe

Jun 29, 2025
pulisher
Jun 27, 2025

Aurinia (AUPH) Surges 7.5%: Is This an Indication of Further Gains? - Yahoo Finance

Jun 27, 2025
pulisher
Jun 26, 2025

Aurinia shares rise ahead of key autoimmune therapy data - Proactive financial news

Jun 26, 2025
pulisher
Jun 21, 2025

Shareholders in Aurinia Pharmaceuticals (NASDAQ:AUPH) have lost 50%, as stock drops 5.0% this past week - simplywall.st

Jun 21, 2025
pulisher
Jun 15, 2025

With 51% institutional ownership, Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) is a favorite amongst the big guns - Yahoo Finance

Jun 15, 2025
pulisher
Jun 12, 2025

Oral Proteins & Peptides Market worth US$24.00 billion by 2030 with 22.1% CAGR | MarketsandMarkets™METRO - METRO - NEWS CHANNEL NEBRASKA

Jun 12, 2025
pulisher
Jun 11, 2025

California State Teachers Retirement System Sells 13,824 Shares of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) - Defense World

Jun 11, 2025
pulisher
Jun 11, 2025

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Shares Sold by Bank of America Corp DE - Defense World

Jun 11, 2025
pulisher
Jun 10, 2025

Are Options Traders Betting on a Big Move in Aurinia Pharmaceuticals (AUPH) Stock? - MSN

Jun 10, 2025

Aurinia Pharmaceuticals Inc Stock (AUPH) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading

Aurinia Pharmaceuticals Inc Stock (AUPH) Insider Trading

Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total
Greenleaf Peter
Chief Executive Officer
Mar 03 '25
Sale
8.00
195,593
1,564,744
1,953,892
Greenleaf Peter
Chief Executive Officer
Mar 04 '25
Sale
7.92
164,947
1,306,380
1,788,945
Keenan Greg
Chief Medical Officer
Mar 03 '25
Sale
8.00
12,239
97,912
161,789
Miller Joseph M
Chief Financial Officer
Mar 03 '25
Sale
8.00
61,859
494,872
633,515
Miller Joseph M
Chief Financial Officer
Mar 04 '25
Sale
7.92
56,154
444,740
577,361
Robertson Stephen P.
EVP, General Counsel
Mar 03 '25
Sale
8.00
64,872
518,976
566,883
Robertson Stephen P.
EVP, General Counsel
Mar 04 '25
Sale
7.92
57,607
456,247
509,276
Donley Matthew Maxwell
Chief Operating Officer
Mar 03 '25
Sale
8.00
65,902
527,216
739,456
Donley Matthew Maxwell
Chief Operating Officer
Mar 04 '25
Sale
7.92
58,991
467,209
680,465
TANG KEVIN
Director
Mar 04 '25
Buy
7.96
748,038
5,953,304
10,029,500
$22.87
price up icon 4.91%
$36.01
price down icon 0.25%
$103.44
price up icon 0.51%
$28.01
price up icon 5.54%
$114.60
price up icon 2.84%
biotechnology ONC
$294.83
price down icon 0.26%
Cap:     |  Volume (24h):